FDA approves a first-of-its-kind eye implant that slows vision loss in rare eye disease

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss. That changed on March 6, 2025, with the approval of ENCELTO (revakinagene taroretcel-lwey), a surgically implanted device designed to preserve sight in people with this condition.

👉 Full Story